A Phase 2, Open-Label Study to Evaluate the Safety, Efficacy and Systemic Exposure of VP-102 Topical Film Forming Solution [0.7% (w/v) in Subjects (2 Years and Older) With Molluscum Contagiosum

Trial Profile

A Phase 2, Open-Label Study to Evaluate the Safety, Efficacy and Systemic Exposure of VP-102 Topical Film Forming Solution [0.7% (w/v) in Subjects (2 Years and Older) With Molluscum Contagiosum

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Aug 2018

At a glance

  • Drugs Cantharidin
  • Indications Molluscum contagiosum
  • Focus Therapeutic Use
  • Sponsors Verrica Pharmaceuticals
  • Most Recent Events

    • 07 Aug 2018 According to a Verrica Pharmaceuticals media release, complete clinical results from enrolled patients expected in the second half of 2018.
    • 12 Jun 2018 Planned End Date changed from 9 May 2018 to 25 Jun 2018.
    • 12 Jun 2018 Planned primary completion date changed from 25 Apr 2018 to 25 Jun 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top